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The proteins of the Bcl-2 family are important regulators of programmed cell death. Structural studies of Bcl-2 family members have
provided many important insights into their molecular mechanism of action and how members of this family interact with one another. To
date, structural studies have been performed on six Bcl-2 family members encompassing both anti- (Bcl-xL, Bcl-2, KSHV-Bcl-2, Bcl-w) and
pro-apoptotic (Bax, Bid) members. They all show a remarkably similar fold despite an overall divergence in amino acid sequence and
function (pro-apoptotic versus anti-apoptotic). The three-dimensional structures of Bcl-2 family members consist of two central,
predominantly hydrophobic a-helices surrounded by six or seven amphipathic a-helices of varying lengths. A long, unstructured loop is
present between the first two a-helices. The structures of the Bcl-2 proteins show a striking similarity to the overall fold of the pore-forming
domains of bacterial toxins. This finding led to experiments which demonstrated that Bcl-xL, Bcl-2, and Bax all form pores in artificial
membranes. A prominent hydrophobic groove is present on the surface of the anti-apoptotic proteins. This groove is the binding site for
peptides that mimic the BH3 region of various pro-apoptotic proteins such as Bak and Bad. Structures of Bcl-xL in complex with these BH3
peptides showed that they bind as an amphipathic a-helix and make extensive hydrophobic contacts with the protein. These data have not
only helped to elucidate the interactions important for hetero-dimerization of Bcl-2 family members but have also been used to guide the
discovery of small molecules that block Bcl-xL and Bcl-2 function. In the recently determined structure of the anti-apoptotic Bcl-w protein,
the protein was also found to have a hydrophobic groove on its surface capable of binding BH3-containing proteins and peptides. However,
in the native protein an additional carboxy-terminal a-helix interacts with the hydrophobic groove. This is reminiscent of how the carboxy-
terminal a-helix of the pro-apoptotic protein Bax binds into its hydrophobic groove. This interaction may play a regulatory role and for Bax
may explain why it is found predominately in the cytoplasm prior to activation. The hydrophobic groove of the pro-apoptotic protein, Bid
protein, is neither as long nor as deep as that found in Bcl-xL, Bcl-2, or Bax. In addition, Bid contains an extra a-helix, which is located
between a1 and a2 with respect to Bcl-xL, Bcl-2, and Bax. Although there are still many unanswered questions regarding the exact
mechanism by which the Bcl-2 family of proteins modulates apoptosis, structural studies of these proteins have deepened our understanding
of apoptosis on the molecular level.
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1. Introduction the accumulation of cells and the inability to respondProgrammed cell death (apoptosis) plays a vital role in
normal development, tissue homeostasis, and the removal of
damaged and infected cells. Disruption of the normal
apoptotic process is implicated in a variety of human
diseases [1,2]. For example, in many forms of cancer, an
imbalance between pro- and anti-apoptotic proteins leads to0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2003.08.012
* Corresponding author. Tel.: +1-847-937-1201; fax: +1-847-935-
5165.
E-mail address: stephen.fesik@abbott.com (S.W. Fesik).correctly to apoptotic stimuli. As a consequence, these
cancers do not respond well to cancer therapies that rely
on the induction of apoptosis for their effect [3]. Removal of
autoreactive T cells after an immune response also depends
on apoptosis. Disruption of the process can lead to the auto-
immune lymphoproliferative syndrome (ALPS) [4]. Insuf-
ficient apoptosis can also lead to persistent infections due to
a failure to eradicate bacteria or virus-infected cells. Equally
important are diseases characterized by inappropriate or
excessive apoptosis. Several neurodegenerative disorders
such as Alzheimer’s, Parkinson’s and Huntington’s diseases
are characterized by the premature loss of specific neurons
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muscular movements, and depression [3]. Excessive apo-
ptosis also contributes to the damage caused by inflamma-
tion, spinal muscular atrophy, myocardial infarction, and
stroke [1,5,6].
Because of its fundamental importance, programmed cell
death is a highly regulated pathway. One important set of
proteins involved in the regulation of apoptosis is the Bcl-2
family. To date, over 25 Bcl-2 family members have been
identified [2,7]. These can be broadly divided into two
classes: those that inhibit apoptosis and those that promote
apoptosis. Homeostasis is maintained by controlling the
amount of active pro- and anti-apoptotic family members
along with tissue-specific patterns of expression. Stimuli,
such as DNA damage, lead to increased expression of pro-Fig. 1. Sequence alignment of Bcl-2 family proteins for which structural informat
with rectangular boxes. Helices 1–8 for Bcl-xL are shown above the sequence
transmembrane helix of Bcl-xL, Bcl-2, and KSHV-Bcl-2 is shown above the sequ
residues, while green boxes highlight conservative substitutions.apoptotic family members. This disrupts the fine balance
between pro- and anti-apoptotic proteins and leads to
programmed cell death.
The pro-survival class of Bcl-2 family members has been
divided into two subclasses based on the presence of one or
more ‘‘Bcl-2 homology’’ (BH) regions (Fig. 1) [7]. Four of
these regions (BH1–4) of sequence homology have been
identified, and each Bcl-2 family member contains at least
one of them. Several members of the pro-survival subclass,
such as Bcl-2, Bcl-xL, Bcl-w, and the Ced-9 protein from C.
elegans, possess all four BH regions. Others, such as Mcl-1,
the BHRF1 protein from Epstein–Barr virus, and KSHV-
Bcl-2 from Kaposi sarcoma virus, only possess strong
sequence homology in the BH1, BH2, and BH3 regions.
Mutagenesis studies indicate that the BH1, BH2, and BH3ion is known. Bcl-2 homolgy ‘‘BH’’ regions present in Bcl-xL are indicated
along with helix 9 of Bax and helix 9 of Bcl-w. In addition, the putative
ences. For the aligned sequences, black boxes highlight strictly conserved
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of these proteins [7]. For the pro-apoptotic proteins, mem-
bers of the Bax subclass possess sequence homology for the
BH1, BH2, and BH3 regions while members of the BH3
subclass have strong homology only in the BH3 region. Pro-
apoptotic family members that contain BH1 and BH2
regions such as Bax can promote apoptosis through their
interactions with mitochondrial membranes. This activity is
independent from their ability to interact with anti-apoptotic
proteins. The BH3 region is responsible for mediating the
interactions with anti-apoptotic proteins and the ability of
the proteins to promote programmed cell death [8]. Peptides
derived from the BH3 regions of pro-apoptotic Bcl-2 family
members can bind to anti-apoptotic family members such as
Bcl-xL and modulate Bcl-2 regulated apoptotic pathways in
living cells [9].
Besides the BH regions, many of the Bcl-2 family
members possess a carboxy-terminal hydrophobic domain,
which is predicted to be responsible for membrane locali-
zation [7,10]. Patterns of membrane localization differ
between the anti-apoptotic and pro-apoptotic proteins. For
example, Bcl-2 has been shown to reside on the cytoplasmic
face of the mitochondrial outer membrane. This membrane
anchoring may play a key role in the ability of Bcl-2 to
modulate mitochondrial membrane integrity. Mitochondrial
dysfunction, in which cytochrome c is released from the
intermembrane space, is a critical step in the initiation of
apoptosis [10] and is inhibited by Bcl-2 and Bcl-xL. In
contrast to Bcl-2 and Bcl-xL, pro-apoptotic family members
such as Bax and Bid are found mainly in the cytosol and are
only localized to the mitochondrial membrane upon activa-
tion [11,12].
Structural studies of Bcl-2 family members have provid-
ed many insights into the molecular mechanism of apoptosis
and how Bcl-2 family members interact with one another.
Here we review the three-dimensional structures of the Bcl-
2 proteins and how this structural information has improved
our understanding of apoptosis at the molecular level. We
describe the structures of the anti-apoptotic proteins, Bcl-xL,
Bcl-2, a Bcl-2 homolog from the Kaposi Sarcoma virus, and
Bcl-w, as well as the structure of Bcl-xL in complex with
BH3-derived peptides from Bak and Bad. In addition, we
review the structural data on the pro-apoptotic proteins Bax
and Bid.2. Bcl-xL
The first published structure of a Bcl-2 family member
was that of human Bcl-xL determined by X-ray crystallog-
raphy and NMR spectroscopy [13]. The study was con-
ducted on a biologically active form of the protein that
lacked the carboxy-terminal transmembrane region. The
overall structure of the protein consists of eight a-helices
connected by loops of varying length (Fig. 2A). Two central
helices (a5 and a6) form the core of the protein. These twohelices are predominately hydrophobic and are flanked on
one side by a3 and a4, and on the other side by a1 and a2.
The signature ‘‘NWGR’’ sequence, which is highly con-
served among Bcl-2 family members, directly precedes a5.
In Bcl-xL, this region appears to play both an important
structural and functional role. Structurally, the tryptophan
residue makes extensive hydrophobic contacts with residues
in a7 and a8. The arginine residue also plays a key
functional role in the binding of Bcl-xL to pro-apoptotic
proteins and peptides such as Bak and Bad (see below).
An unusual feature of the Bcl-xL protein is the presence
of a long loop between a1 and a2. This loop is largely
unstructured as evidenced by the lack of electron density for
residues 28 to 80 and the lack of medium- and long-range
NOEs for these residues. In addition, the amino acid
sequence of this region is highly variable among Bcl-2
family members.
Based on these observations, a mutant protein was
constructed in which residues 26–83 of Bcl-xL were deleted
and replaced by four alanines. The mutant protein was able
to inhibit programmed cell death better than the wild-type
protein upon interleukin-3 withdrawal in FL5.12 cells [13].
These results suggested that the loop is not involved in the
anti-apoptotic activity of Bcl-xL, and may even play a role
in the negative regulation of Bcl-xL function. Indeed, it has
been shown that phosphorylation of Ser 70 of Bcl-2, which
possesses an analogously long loop, abrogates its anti-
apoptotic function [14]. Furthermore, proteolytic cleavage
of the Bcl-2 loop at Asp 34 by caspase-3 converts it from an
anti-apoptotic protein to a pro-apoptotic protein [15].
The three-dimensional structure of Bcl-xL also provided
insight into the significance of the BH homology regions
(Fig. 2A). The BH1, BH2, and BH3 regions are proximal to
one another and define the top of an elongated hydrophobic
groove on the surface of the protein (Fig. 2B). The bottom
of the groove is formed by a3 and a4. This hydrophobic
groove was postulated to be the interaction site for the pro-
apoptotic members of the Bcl-2 family such as Bak and
Bad, which was later confirmed by the NMR structure of the
Bcl-xL/Bak peptide complex [16].
Another key observation was that the three-dimensional
structure of Bcl-xL resembles the membrane insertion
domains of diphtheria toxin and of the colicins [13]. Like
Bcl-xL, these domains contain two hydrophobic a-helices
which are long enough to span a bilayer. Based on this
structural similarity, it was postulated that the Bcl-2 family
of proteins may also form pores in membranes [13].
Subsequent studies have shown that Bcl-xL, Bcl-2, and
Bax can all form ion-conducting channels when incorporat-
ed into synthetic lipid bilayers [17–19]. However, it is
unclear how the pore-forming ability of the Bcl-2 family
of proteins regulates the release of cytochrome c and
controls apoptosis at the molecular level. In an attempt to
provide information on the conformation of Bcl-xL in a lipid
environment, the structure of Bcl-xL in lipid micelles was
characterized [20]. Upon interaction with dodecylphospho-
Fig. 2. Ribbon representations of (A) Bcl-xL [13] and (C) Bcl-2 [21]. For Bcl-xL, the BH1 region is colored magenta, the BH2 region is colored red, the BH3
region is colored green, and the BH4 region is colored yellow. The large unstructured loop between a1 and a2 is omitted for clarity. Helices are numbered with
respect to Fig. 1. Connolly surfaces for (B) Bcl-xL and (D) Bcl-2 were calculated using a probe radius of 1.4 A˚ and are colored as follows: leucine, valine,
isoleucine, phenylalanine, tyrosine, tryptophan, methionine, and alanine are colored yellow; arginine, lysine, and histidine are colored blue; aspartic acid and
glutamic acid are colored red, while all other residues are colored gray. The hydrophobic groove can be clearly seen (yellow) in the surface representations of
both Bcl-xL and Bcl-2.
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change. Based upon an analysis of protein-detergent NOEs
and limited proteolysis, a1, a6, and the initial part of the
long loop after a1 were shown to be embedded in the
hydrophobic core of the micelle. In addition, Bcl-xL is a
monomer when incorporated in the micelle. These results
contradict the findings that Bcl-xL and other family mem-
bers form multimers when incorporated in lipids and ques-
tion the biological relevance of the structural conclusions
obtained from Bcl-xL in micelles.3. Bcl-2
The three-dimensional structure of Bcl-2 has also been
determined [21]. Like Bcl-xL, the NMR structure of Bcl-2 iscomposed of eight a-helices with a hydrophobic groove on
the surface (Fig. 2C and D). The overall backbone RMSD
between Bcl-2 and Bcl-xL is f 1.85 A˚, excluding the loop
between a1 and a2. The largest difference between the
proteins is in the region of a3, which forms part of the
hydrophobic groove. If this region is excluded, the back-
bone RMSD drops to f 1.66 A˚. In Bcl-2 this region
consists of a 310-helix while in Bcl-xL it is a regular a-
helix. In addition, the portion of the hydrophobic groove
defined by a3 on one side is somewhat wider in Bcl-2 than
in Bcl-xL. This difference is likely due to hydrophobic
contacts in Bcl-xL between the side chains of Tyr 120 in
a4 and Tyr 173 in a6, which pull the amino-terminal
portion of a4 and hence the carboxy-terminal portion of
a3 toward a6. In Bcl-2 the residue corresponding to Tyr 120
is an arginine, which forms a different set of interactions.
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proteins, which change the character of the binding groove.
Most notable are differences in sequence at position 104
(Ala in Bcl-xL, Asp in Bcl-2), 108 (Leu in Bcl-xL, Met in
Bcl-2), and 122 (Ser in Bcl-xL, Arg in Bcl-2) (Fig. 3). The
alanine-to-aspartic acid and serine-to-arginine substitutions
would be expected to have the most profound consequences,
since they change the electrostatic character of the groove.
This can be seen by comparing the color-coded surfaces of
Bcl-xL and Bcl-2 in Fig. 2B and D, respectively. In the
surface representation, the wider more elongated groove of
Bcl-2 is also evident. These differences in the topology and
electrostatic character of the binding groove affect the
binding of BH3 peptides from the pro-apoptotic proteins
Bak and Bad. Both peptides bind about 10-fold more
weakly to Bcl-2 than to Bcl-xL [21], suggesting that these
proteins possess a different specificity for binding to pro-
apoptotic family members. It may also have important
implications in the design of small-molecule modulators
of apoptosis. Based on the structures, it may be possible to
design Bcl-xL selective, Bcl-2-selective, or inhibitors that
bind to both of these proteins.4. Bcl-xL/Bak peptide complex
Mutational studies of Bcl-xL suggested that an extensive
surface, including the BH1 and BH2 regions, is necessary
for hetero-dimerization with pro-apoptotic family members
such as Bak. However, corresponding studies of pro-apo-
ptotic members indicated that only a small portion of the
protein involving the BH3 region is required for binding to
Bcl-xL [8,22,23]. Indeed, a short 16-residue peptide fromFig. 3. Hydrophobic groove of Bcl-xL [13] (left) and Bcl-2 [21] (right) highlightin
positions 104 (Ala in Bcl-xL, Asp in Bcl-2), 108 (Leu in Bcl-xL, Met in Bcl-2),
arginine change would be expected to have the largest effect on the character ofthe BH3 region of Bak was found to bind to Bcl-xL with an
affinity (Kd) of 340 nM [16]. Furthermore, peptides com-
prising the BH3 domain of Bak were shown to induce
apoptosis in HeLa cells [24].
To determine the molecular basis for hetero-dimerization
between members of the Bcl-2 family, a three-dimensional
structure was determined by NMR of a complex between
Bcl-xL and a peptide from the BH3 region of the pro-
apoptotic protein Bak [16]. The structure was solved using a
truncated version of Bcl-xL in which both the membrane-
spanning helix and the large, unstructured loop between a1
and a2 were deleted. The three-dimensional structure of the
truncated Bcl-xL protein in the complex was found to be
very similar to that of the free protein with the wild-type
loop intact that was described in Section 2. The Bak peptide
binds to the hydrophobic groove formed on the surface of
the protein by the BH1-3 regions of Bcl-xL and adopts an
amphipathic a-helix (Fig. 4A). Several hydrophobic resi-
dues of the peptide (Val 74, Leu 78, Ile 81, and Ile 85) point
into this groove and make contact with hydrophobic resi-
dues (Phe 97, Tyr 101, Phe 105, Leu 108, Val 126, Leu 130,
Val 141Val) of Bcl-xL (Fig. 4B).
The importance of specific interactions between Bcl-xL
and the Bak peptide was investigated by preparing alanine
mutants of the Bak peptide and testing them for binding to
Bcl-xL [16]. The largest effect on binding was observed by
substituting Leu 78 with alanine which caused a decrease in
the affinity of the peptide nearly 800-fold. Substitution of Ile
85, which is located on the same side of the amphipathic a-
helix, also significantly decreased peptide affinity. These
results clearly demonstrate the importance of hydrophobic
interactions in complex formation. In addition to hydropho-
bic interactions, charged side chains of the peptide (Arg 76,g residues which differ between the two proteins. Differences are located at
and 122 (Ser in Bcl-xL, Arg in Bcl-2). Of these differences, the serine-to-
the groove.
Fig. 4. (A) Connolly surface and (B) ribbon representation for Bcl-xL
complexed to a 16-residue peptide from the Bak protein [16]. The sequence
of the Bak peptide is: GQVGRQLAIIGDDINR. The protein surface is
color-coded as in Fig. 2. The Bak peptide binds to Bcl-xL as an amphipathic
a-helix which is stabilized by a number of hydrophobic contacts with the
protein and via an electrostatic interaction between Asp 83 of the peptide
and Arg 139 of Bcl-xL. In (A) the key hydrophobic residues of the peptide
are numbered with respect to the Bak protein while in (B) the key residues
of the Bcl-xL hydrophobic groove are labelled.
Fig. 5. (A–F) Small-molecule inhibitors of either Bcl-xL or Bcl-2 [26–32].
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contributions to binding based on the structure. In the
structure of the complex, Asp 83 of the peptide is close to
Arg 139 of Bcl-xL, which is consistent with the 120-fold
decrease in binding affinity observed when Asp 83 was
mutated to an alanine. Analogously, mutation of Arg 139,
which is completely conserved within the BH3 domains of
Bcl-2 family members, to glutamine reduces both the anti-
apoptotic activity of Bcl-xL and its affinity for the pro-
apoptotic Bax protein [23]. On the other hand, mutation of
Asp 84 of the Bak peptide to alanine has no effect on the
affinity of the peptide for Bcl-xL despite the fact that it is
proximal to Arg 100 of the protein.Currently, no structural data are available for full-length
Bak. However, a model of the Bak protein was constructed
based on its homology with Bcl-xL [16]. In this model, the
key hydrophobic side chains of the BH3 region of Bak (Val
74, Leu 78, Ile 81, and Ile 85) point toward the interior of
the protein and would thus be unavailable to interact with
Bcl-xL. This model for full-length Bak would require a
conformational change in Bak to occur in order for these
residues to be exposed.
Due to their importance in keeping cancer cells alive,
Bcl-xL and Bcl-2 are considered relevant targets for cancer
chemotherapy. In fact, Bcl-2 anti-sense nucleotides are
currently being tested in clinical trials for the treatment of
cancer [25]. In addition, by utilizing the structure of the Bcl-
xL/Bak peptide complex, small molecule inhibitors of Bcl-
xL and Bcl-2 have been designed.
Wang et al. [26] were the first to report a small-molecule
inhibitor of Bcl-2. These workers built a model of Bcl-2
based on the structure of the Bcl-xL/Bak peptide complex
and subsequently employed a computer docking strategy to
screen 193,833 compounds from the Available Chemicals
Directory. They identified the molecule shown in Fig. 5A
and using a fluorescence polarization-based assay deter-
mined its IC50 for Bcl-2 to be f 9 AM. In addition, they
showed that this compound does in fact induce apoptosis in
HL-60 cells. In another study using computer-based screen-
ing, Enyedy et al. [27] searched the National Cancer
Institute 3D database of 206,876 organic compounds to
identify Bcl-2 binders. A model of Bcl-2 was created based
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complex. The docking exercise yielded 35 potential binders,
seven of which were shown to bind to Bcl-2 with IC50s
between 1.6 and 14.0 AM. The compound shown in Fig. 5B
was the most effective in an anti-proliferation assay using
HL-60 cells with an IC50 of 4 AM.
The structure of the Bcl-xL/Bak peptide complex has also
been used to complement the results of high-throughput
screening. In 2001, Degterev et al. [28] carried out a
fluorescence polarization-based screen of compound bind-
ing to Bcl-xL. Out of 16,320 compounds tested, two series
emerged with single-digit micro molar potency (Fig. 5C and
D). The binding of these compounds to Bcl-xL was con-
firmed by NMR, and, models were constructed of the
complex using the chemical shift perturbation method
[29]. These compounds were shown to induce apoptosis
in Jurkat cells which overexpressed Bcl-xL.
Based on the observation that members of the Bcl-2
family can affect mitochondrial integrity, Tzung et al. [30]
hypothesized that small molecules which are known to
effect mitochondrial respiration might directly trigger an
apoptotic response. To test this hypothesis, they screened
various small molecule inhibitors of respiration in isogenic
hepatocyte cell lines with graded expression of Bcl-xL. For
antimycin A3 (Fig. 5E), an inhibitor of electron transfer at
complex III, they found that rather than protect cells from
apoptosis, Bcl-xL actually enhanced antimycin A3-induced
apoptosis. They went on to show that this effect is mediated
through the binding of antimycin A3 to the hydrophobic
groove of Bcl-xL and using the structure of the Bcl-xL/Bak
peptide complex, they constructed a model for the binding
of antimycin A3 to the hydrophobic groove of Bcl-xL.
Another approach for identifying small molecules that
bind to Bcl-xL involved the design of peptidomimetics [31].
Based on the structure of the Bcl-xL/Bak peptide complex,
Kutzki et al. [32] synthesized a number of terphenyl
derivatives designed to mimic the amphipathic a-helix of
Bak that was shown to bind into the hydrophobic groove of
Bcl-xL. The best of these is shown in Fig. 5F. It binds to
Bcl-xL with a Kd of 114 nM. Docking studies involving this
compound suggest that this molecule fits into the hydro-
phobic groove of the protein in a similar orientation as the
Bak peptide. Further evidence to support this hypothesis
involved NMR experiments to identify key residues in the
groove that experienced chemical shift changes upon bind-
ing of the compound.Fig. 6. Connolly surface for the complex of Bcl-xL with a 25-residue
peptide derived from the Bad protein [35]. The sequence of the Bad pep-
tide is: NLWAAQRYGRELRRMS DEFVDSFKK. As with Bak peptide
binding to Bcl-xL, the Bad peptide binds into the groove as an amphipathic
a-helix. Protein surface is color-coded as in Fig. 2. The key hydrophobic
residues of the peptide are labelled along with the critical aspartic acid
residue (Asp 156).5. Bcl-xL/Bad peptide complex
Like Bak, the pro-apoptotic protein Bad binds to Bcl-xL.
However, unlike the tight binding observed with the Bak
16-mer, an analogous 16-residue peptide from the BH3
region of Bad displayed only weak affinity for Bcl-xL
(Kd>50 AM). It was found that tight binding of the Bad
peptide (Kdf 6 nM) requires five additional residues at theamino terminus and four residues at the carboxy terminus
[33,34]. The rationale for the importance of the residues for
complex formation was examined in structural studies of the
complex and binding studies of mutant Bad peptides [35].
The overall structure of the Bcl-xL/Bad peptide complex
was found to be very similar to that of the Bcl-xL/Bak
peptide complex (Fig. 6). Like the Bak peptide, the Bad 25-
mer binds as an amphipathic a-helix, and similar interac-
tions stabilize complex formation. The additional asparagine
and tryptophan residues at the amino terminus of the Bad
peptide are completely solvent exposed; whereas, Leu 141,
Ala 144, and Ala 145 contact the protein. At the carboxy
terminus of the Bad peptide, only the added Phe makes
contact with the protein. Surprisingly, mutation of the five
additional residues at the amino terminus or the four
additional residues at the carboxy terminus to either alanine
(or glycine, in the case of Ala 144 and Ala 145) had
essentially no effect on the ability of the Bad 25-mer to
bind to Bcl-xL. Furthermore, mutation of individual residues
of the Bad peptide that contact the protein in the Bcl-xL/Bad
structure to the corresponding residue in Bak did not
improve the affinity of the Bad 16-mer for Bcl-xL with
the exception of the carboxy-terminal aspartic acid. When
this residue was mutated to an arginine, the corresponding
residue in the Bak peptide, the affinity of the Bad 16-mer for
Bcl-xL improved about 15-fold. Examination of the struc-
ture of the Bad 25-mer bound to Bcl-xL revealed that this
aspartic acid residue (Asp 160) is predicted to be one helical
turn away from another aspartic acid (Asp 156) (Fig. 6). A
repulsive interaction between these negatively charged res-
idues would be expected to disfavor helix formation. This
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tant role in the binding of the Bad peptide to Bcl-xL. To test
this hypothesis, two mutant 16-residue Bad peptides were
designed which would be predicted to maintain the protein
contacts of the longer Bad peptide but have an increased
propensity to form an a-helix compared to the wild-type 16-
mer. These peptides showed a 100-fold increase in affinity
for Bcl-xL compared to the original 16-residue Bad peptide
and thus confirmed the importance of helix propensity for
the binding of BH3 peptides to Bcl-xL.6. Bax
The overall fold of the pro-apoptotic protein Bax resem-
bles that of Bcl-xL and Bcl-2 [36]. Bax has seven amphi-
pathic helices clustered around two central, mostly
hydrophobic a-helices (Fig. 7). Like its anti-apoptotic
counterparts, a long unstructured loop connects a1 with
a2. Helices 2, 3, and 4 are in the same relative orientation as
in Bcl-xL and form a hydrophobic groove. The orientation
and lengths of a5, a6, a7, and a8 are also very similar to
those in Bcl-xL. Helix 9 of Bax, which corresponds to the
transmembrane a-helix of Bcl-xL and Bcl-2, binds into a
hydrophobic groove of the protein. The binding site corre-
sponds to the same site on Bcl-xL which binds to the Bak
and Bad peptides. However, the a-helix from Bax binds in
the groove in the opposite direction compared to how the
Bak and Bad peptides bind to Bcl-xL. In binding into the
groove, a9 not only covers the hydrophobic residues of the
groove, but also buries its own hydrophobic residues. ThisFig. 7. Ribbon representation of Bax [36]. Helices are numbered with
respect to Bcl-xL. Helix 9 (colored red), which corresponds to the putative
transmembrane helix of Bcl-xL and Bcl-2, sits in the groove formed by a2,
a3, a4, and a5. It sits in the hydrophobic groove in a similar manner to that
observed for the Bak and Bad peptides bound to Bcl-xL with the exception
that its direction is reversed.may be important for increasing the solubility of the protein
and contributes to the fact that Bax exists predominantly in
the cytosol before apoptosis induction.
One mechanism proposed for how Bcl-xL and Bcl-2
maintain the apoptotic balance in the cell and prevent
apoptosis is through their ability to hetero-dimerize with
pro-apoptotic Bcl-2 family members. On a molecular level
this involves binding of BH3-containing pro-apoptotic pro-
teins such as Bak and Bax into a hydrophobic groove on the
surface of Bcl-xL or Bcl-2. In the case of Bax, the hydro-
phobic side chains of the BH3 helix, which would presum-
ably be involved in binding to the anti-apoptotic family
members, point inward toward the hydrophobic core of the
protein and are covered by a9. To expose these residues, a
conformational change of Bax would be required in which
a9 disengages from the binding groove and a2 rotates about
its axis to expose these key residues. This conformational
change is analogous to the change proposed for Bak based
on homology modeling studies [16]. It is clear from the Bax
structure that such a rearrangement would disrupt the
hydrophobic core of the protein and is thus unlikely to
occur without a stimulus [36].
It has been suggested that a rapid increase in intracellular
pH upon cytokine withdrawal serves as a trigger for
apoptosis and causes the translocation of Bax into the
mitochondria [37]. In solution, no structural change in
Bax was observed over the pH range of 6 to 8 [36].
Detergents are also known to induce complex formation
of Bax [11]. Titration of Bax with h-octyl glucoside triggers
oligomer formation, which subsequently induces a major
conformational change in the protein. However, the exact
nature of this conformational change has not yet been
elucidated.7. Bcl-w
The structure of the anti-apoptotic protein Bcl-w has
recently been determined by two groups using NMR spec-
troscopy [38,39]. Its overall fold is similar to that found for
Bcl-xL, Bcl-2, and Bax (Fig. 8). Like the other familiy
members, Bcl-w is composed of two, mostly hydrophobic
a-helices surrounded by amphipathic a-helices. Also, anal-
ogous to Bcl-xL, Bcl-2, and Bax, Bcl-w contains a hydro-
phobic groove on its surface.
An interesting feature of the Bcl-w structure is that it has
an additional carboxy-terminal a-helix which sits in the
hydrophobic groove of the protein. This is similar to the
carboxy-terminal a-helix of the pro-apoptotic protein Bax
which also lies in its hydrophobic groove. As would be
expected, this additional carboxy-terminal helix causes a
moderate decrease in the affinity of BH3 proteins and
peptides to Bcl-w. For example, the affinity of the pro-
apoptotic Bim protein for Bcl-w increases threefold upon
removal of this helix [39]. This helix is distinctly more
mobile than the other a-helices of Bcl-w and more mobile
Fig. 8. Ribbon representation of Bcl-w [38]. Helices are numbered with
respect to Bcl-xL. Helix 9 (colored red) binds into the groove formed by a2,
a3, a4, and a5.
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nuclear NOE measurements [39]. The carboxy-terminal a-
helix of Bax has more hydrophobic side chains in contact
with the groove than a9 of Bcl-w, which likely accounts for
its restricted mobility. While the extra a-helix of Bax is
believed to play a regulatory role, it is currently unclear
whether the extra helix of Bcl-w is also involved in
regulation of the protein’s activity.Fig. 9. (A) Ribbon representation of Bid [40]. Helices are numbered with
respect to Bcl-xL. Bid contains an extra a-helix between a1 and a2 of Bcl-
xL. Structurally, the third helix of Bid corresponds to the second helix of
Bcl-xL. This extra helix is denoted a1V. (B) Connolly surface of Bid with
atoms color-coded as in Fig. 2. The hydrophobic groove (yellow) present
on the surface of the protein is neither as long nor as deep as that found on
the surface of Bcl-xL and Bcl-2.8. Bid
The pro-apoptotic Bid protein is considered to be part of
the ‘‘BH3 only’’ subfamily of Bcl-2 proteins [40] since it is
only homologous to the BH3 region of Bcl-2. Bid is
normally present in an inactive form in the cytosol. In
response to stimuli of the extrinsic, death receptor, pathway,
Bid is proteolytically cleaved by caspase 8 and thus acti-
vated [12]. The activated protein, tBid, translocates to the
mitochondria and serves to link signaling through the FAS
receptor with the mitochondrial death machinery. In the
absence of detergents, only the activated form of the protein,
tBid, binds to Bcl-xL [12].
The solution structure of the Bid protein was determined
using NMR spectroscopy by two groups independently. The
overall fold is remarkably similar to Bcl-xL and Bcl-2
[40,41]. Although it is considered to be a ‘‘BH3 only’’
protein based on sequence homology with Bcl-2, it clearly
contains all of the structural elements of Bcl-2 and Bcl-xL.
Like these anti-apoptotic proteins, Bid has two central,
mostly hydrophobic a-helices surrounded by six amphi-
pathic helices (Fig. 9A). The main difference in overall fold
is in the amino-terminal portion of the protein. Bid containsan extra a-helix compared to Bcl-xL (a1V) that packs in an
anti-parallel fashion against a1. This a-helix is followed by
a long unstructured loop like that found in Bcl-xL, which
connects it to a2. Thus, this third helix of Bid corresponds
to the BH3 region of Bcl-xL. A hydrophobic patch is located
on the surface of Bid (Fig. 9B). This patch is flat and does
not form a deep cleft similar to that observed in the
structures of Bcl-xL and Bcl-2. This difference may explain
why unprocessed Bid cannot form homo- or hetero-dimers
with other Bcl-2 family members. Ile 88, Leu 92, Val 95,
and Met 99 in Bid are homologous to the hydrophobic
residues of the Bak BH3 peptides that were shown to be
important for binding to Bcl-xL [16]. Both Val 95 and Met
99 are exposed in the Bid structure; however, Ile 88 and Leu
92 are partially buried (Fig. 9B). Thus, a change in confor-
mation would be necessary in order for the Bid BH3 domain
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Bcl-xL [40]. Another difference between Bid and Bcl-xL is
the absence of an a-helix corresponding to a7. In Bid, a6 is
followed by the final C-terminal helix of the protein. The
position of this helix is similar to that of a8 in Bcl-xL
(Fig. 2A).
Like Bcl-xL, the long loop in Bid that precedes the BH3
region is susceptible to caspase cleavage. However, in
contrast to Bcl-xL, for which this cleavage converts the
function of the protein from anti-apoptotic to pro-apoptotic,
caspase-8 cleavage of Bid converts it from an inactive form
to a pro-apoptotic form [12]. The activated fragment, tBid,
lacks the first helix, the small additional helix, and part of
the unstructured loop. The first a-helix of Bid has hydro-
phobic interactions with the BH3 region in the native
protein. Removal of this helix would expose a large hydro-
phobic surface on the BH3 helix [40,41]. This activating
cleavage causes a change in the localization of the protein
and the ability of the protein to bind to Bcl-xL.
Conformational changes that are likely to occur because
of this cleavage have not been determined. Initial attempts
to process Bid in an NMR tube did not lead to any clear
changes in the NMR spectrum. When cleaved, the fragment
remained associated with the protein. Chou et al. [40]
proposed that although the amino-terminal fragment of
Bid remains associated with the core of the protein at
NMR concentrations, at low cellular concentrations this
fragment might detach to give the active species.
As discussed above, hetero-dimerization of Bcl-xL or
Bcl-2 with Bax through its BH3 helix would require a
major conformational change in the protein. In Bid, full
exposure of the BH3 domain may be regulated by the
posttranslational cleavage event. The conserved hydropho-
bic residues of the Bid BH3 region are more solvent
exposed than those in Bax [36,40]. Model building studies,
based on this observation and on the solution structures of
the Bcl-xL/Bak peptide complex and that of Bid, suggest
that a hetero-dimer could be formed with only minor
stereochemical conflicts between the two molecules, and
these could be relieved by a slight movement of the Bid
BH3 region [40].Fig. 10. (A) Ribbon representation of KSHV Bcl-2 [43] in the same
orientation as Bcl-xL and Bcl-2 in Fig. 2. Helices are numbered with respect
to Bcl-xL. (B) Connolly surface of KSHV Bcl-2 with atoms color-coded as
in Fig. 2.9. Kaposi sarcoma-associated herpes virus (KSHV)
Bcl-2
When a host is invaded by a virus, the response is
typically the activation of the extrinsic pathway of apoptosis
in the infected cells. A few cells are sacrificed in order to
spare the organism. To counteract the host response, some
viruses have acquired the ability to make anti-apoptotic
proteins [42]. For example, many of the large DNA viruses,
including the poxviruses or gamma herpesviruses, encode a
functional Bcl-2 homolog.
Recently, the NMR structure of a Bcl-2 homolog from
KSHV was reported [43]. Despite the low sequence homol-ogy (Fig. 1) between the viral protein and Bcl-xL and Bcl-2,
its overall fold is very similar (Fig. 10A). Like Bcl-xL and
Bcl-2, KSHV Bcl-2 is an all a-helical protein. Two central
hydrophobic helices (a5 and a6) form the core of the
protein. These are sandwiched between the amphipathic
helices a3 and a4 on one side and by a1 and a2 on the
other side. One difference between the proteins is that the
loop connecting a1 to a2 is much shorter in KSHV Bcl-2
than in Bcl-xL or Bcl-2. In addition, this loop does not
contain a caspase cleavage site like that found in Bcl-2 and
Bcl-xL or the inactivating phosphorylation site which may
allow KSHV Bcl-2 to escape these extra levels of regulation
found in the mammalian proteins [44]. As in other Bcl-2
family members, the signature NWGR sequence at the
beginning of a5 is conserved. The tryptophan residue
clearly serves the same structural role in KSHV Bcl-2 as
it does in Bcl-xL and Bcl-2 and makes intimate hydrophobic
contacts with residues in a7 and a8.
A further similarity of KSHV Bcl-2 to Bcl-xL and Bcl-2
is the presence of a hydrophobic groove on the surface of
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the loop connecting a4 to a5 (Fig. 10B). The position of a3
in KSHV Bcl-2 is similar to that found in Bcl-2. This causes
the hydrophobic pocket to be wider and longer than that
found for Bcl-xL. Hydrophobic residues line the pocket and
are located in a similar position to those found in both Bcl-
xL and Bcl-2. In addition, like Bcl-xL and Bcl-2, KSHV Bcl-
2 binds to the BH3 peptides from the pro-apoptotic proteins
Bak, Bad, and Bax. The Bak 16-mer binds to KSHV Bcl-2
with a dissociation constant < 50 nM while the Bad 25-mer
and a 16-residue peptide from Bax bind with affinities of
3900 and 980 nM, respectively. The greater affinity of
KSHV Bcl-2 for the Bak and Bax peptides compared to
Bad is different from the relative affinities of these peptides
for binding to Bcl-xL and Bcl-2.10. Conclusions
Structural studies of the Bcl-2 family of proteins have
led to a number of key insights on how these proteins
function and how they are regulated at the molecular level.
Despite the sequence diversity among the family members
and the diversity of function, they have a remarkably
similar fold. This fold consists of two central, predominant-
ly hydrophobic a-helices surrounded by six or seven
amphipathic a-helices. The overall topology of the Bcl-2
proteins is similar to that observed for the membrane
translocation domain of the bacterial toxins such as diph-
theria toxin and the colicins. This observation led to experi-
ments which showed that Bcl-xL and Bcl-2 can form pores
in artificial membranes. The structure of the Bcl-xL/Bak
peptide complex provided important insights into the mech-
anism of hetero-dimer formation between pro- and anti-
apoptotic family members. In addition, this structure has
been used to guide the discovery of small molecule inhib-
itors of Bcl-xL and Bcl-2 function. Finally, structural studies
carried out on the pro-apoptotic proteins Bax and Bid raised
important questions regarding the active form of these
proteins in the cell.
From an evolutionary perspective, apoptosis is a very old
and highly conserved process. The strong structural and
sequence homology between the Bcl-2 family members
suggests that they have all descended from a common gene.
While structural studies have provided many insights into
the molecular mechanism of apoptosis and have been used
to guide the design of small molecule that bind to these
proteins, there are still many unanswered questions. The
exact nature of the conformational change required for Bak
or Bax binding to Bcl-xL and Bcl-2 still needs to be
determined as well as any structural changes Bcl-xL, Bcl-
2, and Bax may undergo upon membrane association. In
addition, although both Bcl-xL and Bcl-2 have been shown
to form pores in artificial membranes, it is still unclear how
this relates to the ability of these proteins to regulate
apoptosis. However, despite these and other questions, itis clear that structural studies on the Bcl-2 family of proteins
have, and will continue, to deepen our understanding of the
apoptotic process and may ultimately lead to the develop-
ment of novel therapeutic agents.References
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